In The News
Clyde & Co sued by insurers over indemnity advice
Cornwalls hits back at $4.8M negligence suit by former client
‘Our integrations are on track’: Class action flags WiseTech response to short seller report
Russells partner accused of bullying told lawyer she was ‘very negative’
Top silk to join NSW Supreme Court
NAB accused of rescinding job offer to pregnant employee
Ex-Bulldogs player must produce messages between solicitor and doctor
AI pathology invention just administrative tool, not patentable: IP Australia
Ultimate Fighting Championship gym exec not on the hook for $5M judgment
Child removal class actions launched against NSW, WA
Please login to bookmarkClose

Five years into a preliminary discovery application for a potential patent infringement lawsuit over a biosimilar of its Enbrel medication, Pfizer has partially succeeded in obtaining further documents from Samsung Bioepis.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au